{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T18:35:13Z","timestamp":1793298913476,"version":"4.5.0"},"reference-count":112,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Indian Dermatol Online J"],"published-print":{"date-parts":[[2017]]},"DOI":"10.4103\/2229-5178.209622","type":"journal-article","created":{"date-parts":[[2017,7,5]],"date-time":"2017-07-05T05:46:46Z","timestamp":1499233606000},"page":"235","source":"Crossref","is-referenced-by-count":144,"title":["Topical therapies in psoriasis"],"prefix":"10.4103","volume":"8","author":[{"given":"R","family":"Torsekar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"ManjyotM","family":"Gautam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/2229-5178.209622-1","first-page":"595","volume-title":"Psoriasis in India: Prevalence and pattern","author":"Dogra","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.209622-2","first-page":"859","volume-title":"Psoriasis: Consensus on topical therapies","author":"van","year":"2008","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.209622-3","first-page":"504","volume-title":"Occlusion enhances the efficacy of topical calcipotriol in the treatment of psoriasis vulgaris","author":"Bourke","year":"1993","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/2229-5178.209622-4","first-page":"149","volume-title":"Evaluating the efficacy and safety of calcipotriene\/betamethasone ointment occluded with a hydrogel patch: A 6-week bilaterally controlled, investigator-blinded trial","author":"Patel","year":"2011","journal-title":"Cutis"},{"key":"key-10.4103\/2229-5178.209622-5","first-page":"141","volume-title":"Remission and relapse of chronic plaque psoriasis treated once a week with clobetasol propionate occluded with a hydrocolloid dressing v\/s twice daily treatment with clobetasol propionate alone","author":"Volden","year":"2001","journal-title":"J Dermatol Treat"},{"key":"key-10.4103\/2229-5178.209622-6","first-page":"389","volume-title":"A new calcipotriol\/betamethasone dipropionate formulation (Daivobet) is an effective once-daily treatment for psoriasis vulgaris","author":"Kaufmann","year":"2002","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.209622-7","first-page":"141","volume-title":"Calcipotriol\/betamethasone dipropionate in the treatment of psoriasis vulgaris","author":"Vakirlis","year":"2008","journal-title":"Ther Clin Risk Manag"},{"key":"key-10.4103\/2229-5178.209622-8","first-page":"38","volume-title":"Pharmacotherapy updates: Current therapies and research for common dermatologic conditions.The many roles of salicyclic acid","author":"Del","year":"2005","journal-title":"Skin Aging"},{"key":"key-10.4103\/2229-5178.209622-9","first-page":"26","volume-title":"The stability of dithranol in various bases.Br J Dermatol","author":"Green","year":"1985","journal-title":""},{"key":"key-10.4103\/2229-5178.209622-10","first-page":"292","volume-title":"Patient compliance and disease management in the treatment of psoriasis in the Netherlands","author":"van","year":"2000","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.209622-11","first-page":"380","volume-title":"Emollients, moisturizers, and keratolytic agents in psoriasis","author":"Fluhr","year":"2008","journal-title":"Clin Dermatol"},{"key":"key-10.4103\/2229-5178.209622-12","first-page":"7","volume-title":"Therapeutic moisturizers as adjuvant therapy for psoriasis patients","author":"Gelmetti","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/2229-5178.209622-13","first-page":"505","volume-title":"Management of psoriasis with Aloe vera extract in a hydrophilic cream: A placebo-controlled, double-blind study","author":"Syed","year":"1996","journal-title":"Trop Med Int Health"},{"key":"key-10.4103\/2229-5178.209622-14","first-page":"326","volume-title":"A double-blind, placebo-controlled study of a commercial Aloe vera gel in the treatment of slight to moderate psoriasis vulgaris","author":"Paulsen","year":"2005","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.209622-15","first-page":"943","volume-title":"Topical therapies for localized psoriasis","author":"Witman","year":"2001","journal-title":"Mayo Clin Proc"},{"key":"key-10.4103\/2229-5178.209622-16","first-page":"80","volume-title":"The use of emollients as sophisticated therapy in dermatology","author":"Nola","year":"2003","journal-title":"Acta Dermatovenerol Croat"},{"key":"key-10.4103\/2229-5178.209622-17","first-page":"1012","volume-title":"The anti-psoriatic drug anthralin accumulates in keratinocyte mitochondria, dissipates mitochondrial membrane potential, and induces apoptosis through a pathway dependent on respiratory competent mitochondria","author":"McGill","year":"2005","journal-title":"FASEB J"},{"key":"key-10.4103\/2229-5178.209622-18","first-page":"723","volume-title":"Dithranol","author":"Mahrle","year":"1997","journal-title":"Clin Dermatol"},{"key":"key-10.4103\/2229-5178.209622-19","first-page":"461","volume-title":"Short-contact anthralin therapy for psoriasis","author":"Fleischmann","year":"1987","journal-title":"West J Med"},{"key":"key-10.4103\/2229-5178.209622-20","first-page":"351","volume-title":"Topical preparations for the treatment of psoriasis: A systematic review","author":"Mason","year":"2002","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-21","first-page":"331","volume-title":"Out-patient treatment of psoriasis: Short contact and overnight dithranol therapy compared","author":"Jones","year":"1985","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-22","first-page":"266","volume-title":"A multicentre, parallel-group comparison of calcipotriol ointment and short-contact dithranol therapy in chronic plaque psoriasis","author":"Berth-Jones","year":"1992","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-23","first-page":"139","volume-title":"The efficacy, safety and tolerance of calcitriol 3 microg\/g ointment in the treatment of plaque psoriasis: A comparison with short-contact dithranol","author":"Hutchinson","year":"2000","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.209622-24","first-page":"375","volume-title":"A comparison of twice-daily calcipotriol ointment with once-daily short-contact dithranol cream therapy: Quality-of-life outcomes of a randomized controlled trial of supervised treatment of psoriasis in a day-care setting","author":"de","year":"2008","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-25","first-page":"32","volume-title":"Skin susceptibility to dithranol: Contact allergy or irritation?","author":"Loffler","year":"1999","journal-title":"Eur J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-26","first-page":"73","volume-title":"The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis","author":"Ramsay","year":"1990","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-27","first-page":"951","volume-title":"Anthralin stain removal","author":"Wang","year":"1986","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-28","first-page":"313","volume-title":"The influence of salicylic acid on the in vitro release of anthralin from an oil in water cream","author":"Kneczke","year":"1990","journal-title":"Acta Pharm Nord"},{"key":"key-10.4103\/2229-5178.209622-29","first-page":"20","volume-title":"Short-contact treatment at home with micanol","author":"Volden","year":"1992","journal-title":"Acta Derm Venereol"},{"key":"key-10.4103\/2229-5178.209622-30","first-page":"419","volume-title":"Stability of a novel dithranol ointment formulation, containing ascorbyl palmitate as an anti-oxidant","author":"Weller","year":"1990","journal-title":"J Clin Pharm Ther"},{"key":"key-10.4103\/2229-5178.209622-31","first-page":"91","volume-title":"Dithranol in an emulsifying oil base (bio-wash-oil) for the treatment of psoriasis of the scalp","author":"Wulff-Woesten","year":"2004","journal-title":"Skin Pharmacol Physiol"},{"key":"key-10.4103\/2229-5178.209622-32","first-page":"40","volume-title":"A randomized, double-blind, vehicle-controlled study of a novel liposomal dithranol formulation in psoriasis","author":"Saraswat","year":"2007","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/2229-5178.209622-33","first-page":"229","volume-title":"Treatment of psoriasis","author":"Goeckerman","year":"1925","journal-title":"Northwest Med"},{"key":"key-10.4103\/2229-5178.209622-34","first-page":"1396","volume-title":"Carbazole is a naturally occurring inhibitor of angiogenesis and inflammation isolated from antipsoriatic coal tar","author":"Arbiser","year":"2006","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.209622-35","first-page":"51","volume-title":"Duration of remission of psoriasis therapies","author":"Koo","year":"1999","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-36","first-page":"1258","volume-title":"An evidence-based review of the efficacy of coal tar preparations in the treatment of psoriasis and atopic dermatitis","author":"Slutsky","year":"2010","journal-title":"J Drugs Dermatol"},{"key":"key-10.4103\/2229-5178.209622-37","first-page":"834","volume-title":"Calcipotriol versus coal tar: A prospective randomized study in stable plaque psoriasis","author":"Sharma","year":"2003","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-38","first-page":"579","volume-title":"An open label prospective randomized trial to compare the efficacy of coal tar-salicylic acid ointment versus calcipotriol\/betamethasone dipropionate ointment in the treatment of limited chronic plaque psoriasis","author":"Khandpur","year":"2014","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/2229-5178.209622-39","first-page":"673","volume-title":"A comparative study of calcipotriol ointment and tar in chronic plaque psoriasis","author":"Tham","year":"1994","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-40","doi-asserted-by":"crossref","unstructured":"Lebwohl M, Ali S. Treatment of psoriasis. Part 1. Topical therapy and phototherapy. J Am Acad Dermatol 2001;45:487-98.","DOI":"10.1067\/mjd.2001.117046"},{"key":"key-10.4103\/2229-5178.209622-41","first-page":"216","volume-title":"Tar revisited","author":"Lin","year":"1985","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-42","first-page":"612","volume-title":"Incidence of skin cancers in patients with atopic dermatitis treated with coal tar.A 25-year follow-up study","author":"Maughan","year":"1980","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-43","first-page":"732","volume-title":"Skin carcinoma in patients with psoriasis treated with topical tar and artificial ultraviolet radiation","author":"Stern","year":"1980","journal-title":"Lancet"},{"key":"key-10.4103\/2229-5178.209622-44","first-page":"295","volume-title":"Safety of dermatologic drugs used in pregnant patients with psoriasis and other inflammatory skin diseases","author":"Lam","year":"2008","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-45","first-page":"42","volume-title":"Coal tar 2% foam in combination with a superpotent corticosteroid foam for plaque psoriasis: Case report and clinical implications","author":"Frankel","year":"2010","journal-title":"J Clin Aesthet Dermatol"},{"key":"key-10.4103\/2229-5178.209622-46","first-page":"275","volume-title":"Efficacy and tolerability of a cosmetically acceptable coal tar solution in the treatment of moderate plaque psoriasis: A controlled comparison with calcipotriene (calcipotriol) cream","author":"Alora-Palli","year":"2010","journal-title":"J Clin Dermatol"},{"key":"key-10.4103\/2229-5178.209622-47","first-page":"612","volume-title":"Novel drug delivery systems in topical treatment of psoriasis: Rigors and vigors","author":"Katare","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.209622-48","first-page":"16","volume-title":"The role of salicylic acid in the treatment of psoriasis","author":"Lebwohl","year":"1999","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-49","doi-asserted-by":"crossref","unstructured":"Tiplica GS, Salavastru CM. Mometasone furoate 0.1% and salicylic acid 5% vs. mometasone furoate 0.1% as sequential local therapy in psoriasis vulgaris. J Eur Acad Dermatol Venereol 2009;23:905-12.","DOI":"10.1111\/j.1468-3083.2009.03214.x"},{"key":"key-10.4103\/2229-5178.209622-50","first-page":"43","volume-title":"Topical tacrolimus ointment combined with 6% salicylic acid gel for plaque psoriasis treatment","author":"Carroll","year":"2005","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.209622-51","first-page":"199","volume-title":"Anthralin-salicylic acid therapy of psoriasis.Cignolin-salicylic acid-vaseline treatment and Lasan paste in a right-left comparison","author":"Runne","year":"1974","journal-title":"Hautarzt"},{"key":"key-10.4103\/2229-5178.209622-52","first-page":"63","volume-title":"Short and long-term risks of topical drugs","author":"Zesch","year":"1986","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-53","first-page":"699","volume-title":"Adult salicylate poisoning: Deaths and outcome in patients with high plasma salicylate concentrations","author":"Chapman","year":"1989","journal-title":"Q J Med"},{"key":"key-10.4103\/2229-5178.209622-54","first-page":"307","volume-title":"Salicylate intoxication after use of topical salicylic acid ointment by a patient with psoriasis","author":"P\u00e9c","year":"1992","journal-title":"Cutis"},{"key":"key-10.4103\/2229-5178.209622-55","first-page":"624","volume-title":"Life threatening salicylate poisoning caused by percutaneous absorption in severe ichthyosis vulgaris","author":"Germann","year":"1996","journal-title":"Hautarzt"},{"key":"key-10.4103\/2229-5178.209622-56","first-page":"740","volume-title":"Percutaneous absorption of salicylic acid","author":"Taylor","year":"1975","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.209622-57","first-page":"69","volume-title":"The topical treatment of psoriasis","author":"van","year":"2003","journal-title":"Skin Pharmacol Appl Skin Physiol"},{"key":"key-10.4103\/2229-5178.209622-58","first-page":"618","volume-title":"The macrolide immunosuppressants in dermatology: Mechanisms of action","author":"Marsland","year":"2002","journal-title":"Eur J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-59","first-page":"1101","volume-title":"Topical tacrolimus is not effective in chronic plaque psoriasis.A pilot study","author":"Zonneveld","year":"1998","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.209622-60","first-page":"493","volume-title":"Pimecrolimus: A review","author":"Gupta","year":"2003","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"key-10.4103\/2229-5178.209622-61","first-page":"8","volume-title":"Efficacy of topical calcineurin inhibitors in psoriasis","author":"Wang","year":"2014","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/2229-5178.209622-62","first-page":"A double","volume-title":"1% pimecrolimus, 0.005% calcipotriol, and 0","author":"Kreuter","year":"1&#3","journal-title":""},{"key":"key-10.4103\/2229-5178.209622-63","first-page":"Results of a randomized, open","volume-title":"0.3% tacrolimus gel and 0","author":"Ortonne","year":"5&#3","journal-title":""},{"key":"key-10.4103\/2229-5178.209622-64","first-page":"8","volume-title":"A safety assessment of topical calcineurin inhibitors in the treatment of atopic dermatitis","author":"Lebwohl","year":"2006","journal-title":"MedGenMed"},{"key":"key-10.4103\/2229-5178.209622-65","first-page":"561","volume-title":", Phelps KC, Feldman SR.Psoriasis and pregnancy","author":"Tauscher","year":"2002","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/2229-5178.209622-66","first-page":"76","volume-title":"Tacrolimus ointment is effective for psoriasis on the face and intertriginous areas in pediatric patients","author":"Brune","year":"2007","journal-title":"Pediatr Dermatol"},{"key":"key-10.4103\/2229-5178.209622-67","first-page":"758","volume-title":"Treatment of psoriasis with topical sirolimus: Preclinical development and a randomized, double-blind trial","author":"Ormerod","year":"2005","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-68","first-page":"S129","volume-title":"The pathogenesis of psoriasis and the mechanism of action of tazarotene","author":"Duvic","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-69","doi-asserted-by":"crossref","unstructured":"Weinstein GD, Koo JY, Krueger GG, Lebwohl MG, Lowe NJ, Menter MA, et al. Tazarotene cream in the treatment of psoriasis: Two multicenter, double-blind, randomized, vehicle-controlled studies of the safety and efficacy of tazarotene creams 0.05% and 0.1% applied once daily for 12 weeks. J Am Acad Dermatol 2003;48:760-7.","DOI":"10.1067\/mjd.2003.103"},{"key":"key-10.4103\/2229-5178.209622-70","first-page":"705","volume-title":"Once-daily tazarotene gel versus twice-daily fluocinonide cream in the treatment of plaque psoriasis","author":"Lebwohl","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-71","first-page":"40","volume-title":"Evaluation of topical 0.1% tazarotene cream in the treatment of palmoplantar psoriasis: An observer-blinded randomized controlled study","author":"Mehta","year":"2011","journal-title":"Indian J Dermatol","ISSN":"https:\/\/id.crossref.org\/issn\/0019-5154","issn-type":"print"},{"key":"key-10.4103\/2229-5178.209622-72","doi-asserted-by":"crossref","unstructured":"Kaur I, Dogra S, Jain R, Kumar B. Comparative study of calcipotriol (0.005%) ointment and tazarotene (0.05% and 0.1%) gel in the treatment of stable plaque psoriasis. Indian J Dermatol Venereol Leprol 2008;74:471-4.","DOI":"10.4103\/0378-6323.44302"},{"key":"key-10.4103\/2229-5178.209622-73","first-page":"482","volume-title":"Topical tazarotene vs.coal tar in stable plaque psoriasis","author":"Kumar","year":"2010","journal-title":"Clin Exp Dermatol"},{"key":"key-10.4103\/2229-5178.209622-74","doi-asserted-by":"crossref","unstructured":"Koo JY, Martin D. Investigator-masked comparison of tazarotene gel q.d. plus mometasone furoate cream q.d. vs. mometasone furoate cream b.i.d. in the treatment of plaque psoriasis. Int J Dermatol 2001;40:210-2.","DOI":"10.1046\/j.1365-4362.2001.01167.x"},{"key":"key-10.4103\/2229-5178.209622-75","first-page":"634","volume-title":"Newer trends in the management of psoriasis at difficult to treat locations: Scalp, palmoplantar disease and nails","author":"Handa","year":"2010","journal-title":"Indian J Dermatol Venereol Leprol","ISSN":"https:\/\/id.crossref.org\/issn\/0378-6323","issn-type":"print"},{"key":"key-10.4103\/2229-5178.209622-76","first-page":"235","volume-title":"Short contact therapy with tazarotene in psoriasis vulgaris","author":"Veraldi","year":"2006","journal-title":"Dermatology"},{"key":"key-10.4103\/2229-5178.209622-77","first-page":"713","volume-title":"Genital ulcers in a psoriasis patient using topical tazarotene","author":"Wollina","year":"1998","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-78","first-page":"501","volume-title":"Phase II clinical trial of bexarotene gel 1% in psoriasis","author":"Breneman","year":"2007","journal-title":"J Drugs Dermatol"},{"key":"key-10.4103\/2229-5178.209622-79","first-page":"115","volume-title":"A randomized double blinded, vehicle- controlled, bilateral comparison trail of baxarotene gel 1% versus vehicle gel in combination with NBUVB phototreatment for moderate to severe psoriasis vulgaris","author":"Magliocco","year":"2006","journal-title":"J Am Assoc Dermatol"},{"key":"key-10.4103\/2229-5178.209622-80","first-page":"20","volume-title":"Existence of reservoir in the stratum corneum.Experimental proof","author":"Vickers","year":"1963","journal-title":"Arch Dermatol"},{"key":"key-10.4103\/2229-5178.209622-81","first-page":"181","volume-title":"Regional variation in percutaneous penetration of 14C cortisol in man","author":"Feldmann","year":"1967","journal-title":"J Invest Dermatol"},{"key":"key-10.4103\/2229-5178.209622-82","first-page":"1170","volume-title":"Evaluation of halobetasol propionate ointment in the treatment of plaque psoriasis: Report on two double-blind, vehicle-controlled studies","author":"Bernhard","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-83","doi-asserted-by":"crossref","unstructured":"Blum G, Yawalkar S. A comparative, multicenter, double blind trial of 0.05% halobetasol propionate ointment and 0.1% betamethasone valerate ointment in the treatment of patients with chronic, localized plaque psoriasis. J Am Acad Dermatol 1991;25(6 Pt 2):1153-6.","DOI":"10.1016\/0190-9622(91)70315-S"},{"key":"key-10.4103\/2229-5178.209622-84","first-page":"57","volume-title":"Efficacy and safety of fluticasone propionate 0.005% ointment in the treatment of psoriasis","author":"Olsen","year":"1996","journal-title":"Cutis"},{"key":"key-10.4103\/2229-5178.209622-85","first-page":"269","volume-title":"Intermittent corticosteroid maintenance treatment of psoriasis: A double-blind multicenter trial of augmented betamethasone dipropionate ointment in a pulse dose treatment regimen","author":"Katz","year":"1991","journal-title":"Dermatologica"},{"key":"key-10.4103\/2229-5178.209622-86","first-page":"154","volume-title":"Intermittent topical treatment of psoriasis with clobetasol propionate","author":"Svartholm","year":"1982","journal-title":"Curr Med Res Opin"},{"key":"key-10.4103\/2229-5178.209622-87","first-page":"443","volume-title":"A double-blind, vehicle-controlled study of clobetasol propionate 0.05% (Temovate) scalp application in the treatment of moderate to severe scalp psoriasis","author":"Olsen","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-88","first-page":"628","volume-title":"Betamethasone valerate foam 0.12%: A novel vehicle with enhanced delivery and efficacy","author":"Franz","year":"1999","journal-title":"Int J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-89","first-page":"1","volume-title":"Adverse effects of topical glucocorticosteroids","author":"Hengge","year":"2006","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-90","first-page":"694","volume-title":"Systematic review of the safety of topical corticosteroids in pregnancy","author":"Chi","year":"2010","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-91","first-page":"387","volume-title":"Safety of fluticasone propionate cream 0.05% for the treatment of severe and extensive atopic dermatitis in children as young as 3 months","author":"Friedlander","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-92","first-page":"397","volume-title":"Topical clobetasol propionate in the treatment of psoriasis: A review of newer formulations","author":"Feldman","year":"2009","journal-title":"Am J Clin Dermatol"},{"key":"key-10.4103\/2229-5178.209622-93","first-page":"185","volume-title":"Clobetasol propionate shampoo 0.05% is efficacious and safe for long-term control of moderate scalp psoriasis","author":"Poulin","year":"2010","journal-title":"J Dermatolog Treat"},{"key":"key-10.4103\/2229-5178.209622-94","first-page":"889","volume-title":"Effects of a novel Vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo","author":"Binderup","year":"1988","journal-title":"Biochem Pharmacol"},{"key":"key-10.4103\/2229-5178.209622-95","doi-asserted-by":"crossref","unstructured":"Highton A, Quell J. Calcipotriene ointment 0.005% for psoriasis: A safety and efficacy study. Calcipotriene study group. J Am Acad Dermatol 1995;32:67-72.","DOI":"10.1016\/0190-9622(95)90186-8"},{"key":"key-10.4103\/2229-5178.209622-96","first-page":"S53","volume-title":"Management of psoriasis with calcipotriol used as monotherapy","author":"Ramsay","year":"1997","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-97","first-page":"CD005028","volume-title":"Topical treatments for chronic plaque psoriasis","author":"Mason","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"key-10.4103\/2229-5178.209622-98","first-page":"483","volume-title":"Comparative effects of calcipotriol (MC903) solution and placebo (vehicle of MC903) in the treatment of psoriasis of the scalp","author":"Green","year":"1994","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-99","first-page":"268","volume-title":"A multicenter trial of calcipotriene ointment and halobetasol ointment compared with either agent alone for the treatment of psoriasis","author":"Lebwohl","year":"1996","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-100","first-page":"44","volume-title":"A novel aerosol foam formulation of calcipotriol and betamethasone has no impact on HPA axis and calcium homeostasis in patients with extensive psoriasis vulgaris","author":"Taraska","year":"2016","journal-title":"J Cutan Med Surg"},{"key":"key-10.4103\/2229-5178.209622-101","first-page":"17","volume-title":"Long-term safety of topical calcitriol 3 microg\/g ointment","author":"Gerritsen","year":"2001","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-102","first-page":"414","volume-title":"Long-term efficacy and safety of tacalcitol ointment in patients with chronic plaque psoriasis","author":"van","year":"2002","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-103","first-page":"581","volume-title":"Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol.A double-blind trial","author":"Veien","year":"1997","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-104","first-page":"180","volume-title":"Vitamin D analogs in the treatment of psoriasis: Where are we standing and where will we be going?","author":"Tr\u00e9mezaygues","year":"2011","journal-title":"Dermatoendocrinol"},{"key":"key-10.4103\/2229-5178.209622-105","first-page":"1999","volume-title":"Topical treatment of psoriasis","author":"Laws","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"key-10.4103\/2229-5178.209622-106","first-page":"238","volume-title":"Efficacy and safety of topical calcitriol (1,25-dihydroxyvitamin d3) for the treatment of psoriasis","author":"P\u00e8rez","year":"1996","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-107","first-page":"835","volume-title":"Vitamin D3 analogues","author":"Kragbelle","year":"1996","journal-title":"Dermatol Clin"},{"key":"key-10.4103\/2229-5178.209622-108","first-page":"1010","volume-title":"Compatibility of calcipotriene with other topical medications","author":"Patel","year":"1998","journal-title":"J Am Acad Dermatol"},{"key":"key-10.4103\/2229-5178.209622-109","first-page":"390","volume-title":"Safety and efficacy of calcipotriol ointment (Dovonex) in treating children with psoriasis vulgaris","author":"Darley","year":"1996","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-110","first-page":"21","volume-title":"Similarly potent action of 1,25-dihydroxyvitamin D3 and its analogues, tacalcitol, calcipotriol, and maxacalcitol on normal human keratinocyte proliferation and differentiation","author":"Takahashi","year":"2003","journal-title":"J Dermatol Sci"},{"key":"key-10.4103\/2229-5178.209622-111","first-page":"190","volume-title":"Topical paricalcitol (19-nor-1 alpha, 25-dihydroxyvitamin D2) is a novel, safe and effective treatment for plaque psoriasis: A pilot study","author":"Durakovic","year":"2004","journal-title":"Br J Dermatol"},{"key":"key-10.4103\/2229-5178.209622-112","first-page":"369","volume-title":"Topical becocalcidiol for the treatment of psoriasis vulgaris: A randomized, placebo-controlled, double-blind, multicentre study","author":"Helfrich","year":"2007","journal-title":"Br J Dermatol"}],"container-title":["Indian Dermatology Online Journal"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T13:33:21Z","timestamp":1786714401000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/2229-5178.209622"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017]]},"references-count":112,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2017]]}},"alternative-id":["209622"],"URL":"https:\/\/doi.org\/10.4103\/2229-5178.209622","relation":{},"ISSN":["2229-5178"],"issn-type":[{"value":"2229-5178","type":"print"}],"subject":[],"published":{"date-parts":[[2017]]}}}